Cytomx Therapeutics Stock Net Income
| CTMX Stock | USD 1.02 0.06 6.25% |
CytomX Therapeutics fundamentals help investors to digest information that contributes to CytomX Therapeutics' financial success or failures. It also enables traders to predict the movement of CytomX Stock. The fundamental analysis module provides a way to measure CytomX Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CytomX Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -569 K | -597.5 K | |
| Net Loss | -10.2 M | -10.7 M | |
| Net Loss | -104.3 M | -109.5 M | |
| Net Loss | (0.01) | (0.01) | |
| Net Loss | (0.17) | (0.16) |
CytomX | Net Income |
CytomX Therapeutics Company Net Income Analysis
CytomX Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current CytomX Therapeutics Net Income | (569 K) |
Most of CytomX Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CytomX Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
CytomX Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for CytomX Therapeutics is extremely important. It helps to project a fair market value of CytomX Stock properly, considering its historical fundamentals such as Net Income. Since CytomX Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of CytomX Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of CytomX Therapeutics' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
CytomX Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, CytomX Therapeutics reported net income of (569,000). This is 100.17% lower than that of the Biotechnology sector and 100.81% lower than that of the Health Care industry. The net income for all United States stocks is 100.1% higher than that of the company.
CytomX Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CytomX Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CytomX Therapeutics could also be used in its relative valuation, which is a method of valuing CytomX Therapeutics by comparing valuation metrics of similar companies.CytomX Therapeutics is currently under evaluation in net income category among its peers.
CytomX Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of CytomX Therapeutics from analyzing CytomX Therapeutics' financial statements. These drivers represent accounts that assess CytomX Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of CytomX Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 376.7M | 302.3M | 277.8M | 105.2M | 114.4M | 108.7M | |
| Enterprise Value | 213.2M | 135.3M | 90.3M | (70.4M) | 111.2M | 105.6M |
CytomX Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in CytomX Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of CytomX Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing CytomX Therapeutics' value.| Shares | Rtw Investments, Llc | 2024-06-30 | 1.2 M | Blackrock Inc | 2024-06-30 | 1.1 M | Renaissance Technologies Corp | 2024-09-30 | 1 M | Altium Capital Management, Lp | 2024-09-30 | 915 K | Adar1 Capital Management Llc | 2024-09-30 | 904 K | Geode Capital Management, Llc | 2024-09-30 | 803.5 K | Two Sigma Investments Llc | 2024-09-30 | 471.5 K | Sei Investments Co | 2024-06-30 | 382.7 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 377 K | Tang Capital Management Llc | 2024-09-30 | 7.8 M | Hhg Plc | 2024-06-30 | 6.3 M |
CytomX Fundamentals
| Return On Equity | -54.75 | ||||
| Return On Asset | 0.0233 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | (27.17 M) | ||||
| Shares Outstanding | 78.26 M | ||||
| Shares Owned By Insiders | 1.00 % | ||||
| Shares Owned By Institutions | 65.62 % | ||||
| Number Of Shares Shorted | 4.44 M | ||||
| Price To Earning | (11.41) X | ||||
| Price To Book | 5.04 X | ||||
| Price To Sales | 0.63 X | ||||
| Revenue | 101.21 M | ||||
| Gross Profit | 53.16 M | ||||
| EBITDA | (4.31 M) | ||||
| Net Income | (569 K) | ||||
| Cash And Equivalents | 194.29 M | ||||
| Cash Per Share | 2.94 X | ||||
| Total Debt | 13.97 M | ||||
| Debt To Equity | 0.67 % | ||||
| Current Ratio | 2.05 X | ||||
| Book Value Per Share | (0.30) X | ||||
| Cash Flow From Operations | (56.03 M) | ||||
| Short Ratio | 4.41 X | ||||
| Earnings Per Share | 0.16 X | ||||
| Price To Earnings To Growth | (1.80) X | ||||
| Target Price | 5.29 | ||||
| Number Of Employees | 120 | ||||
| Beta | 1.06 | ||||
| Market Capitalization | 79.82 M | ||||
| Total Asset | 201.79 M | ||||
| Retained Earnings | (723.45 M) | ||||
| Working Capital | 27.02 M | ||||
| Current Asset | 189.75 M | ||||
| Current Liabilities | 15.74 M | ||||
| Net Asset | 201.79 M |
About CytomX Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CytomX Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CytomX Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CytomX Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for CytomX Stock Analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.